Oliver H KrÃ¤mer

List of Publications by Year
in descending order

114 papers	5,411 citations	94381 37 h-index	88593 70 g-index
118 all docs	118 docs citations	118 times ranked	8159 citing authors

#	Article	IF	Citations
1	Acetylation of non-histone proteins modulates cellular signalling at multiple levels. International Journal of Biochemistry and Cell Biology, 2009, 41, 185-198.	1.2	613
2	The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO Journal, 2003, 22, 3411-3420.	3.5	460
3	Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism, 2001, 12, 294-300.	3.1	238
4	A phosphorylation-acetylation switch regulates STAT1 signaling. Genes and Development, 2009, 23, 223-235.	2.7	227
5	Acetylation of Stat1 modulates NF-ÂB activity. Genes and Development, 2006, 20, 473-485.	2.7	189
6	Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer, 2005, 104, 2717-2725.	2.0	164
7	HDACi â€“ Targets beyond chromatin. Cancer Letters, 2009, 280, 160-167.	3.2	146
8	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136
9	HDAC2: a critical factor in health and disease. Trends in Pharmacological Sciences, 2009, 30, 647-655.	4.0	133
10	Nuclear export is essential for the tumorâ€promoting activity of survivin. FASEB Journal, 2007, 21, 207-216.	0.2	116
11	Drugging the HDAC6â€“HSP90 interplay in malignant cells. Trends in Pharmacological Sciences, 2014, 35, 501-509.	4.0	110
12	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax, 2015, 70, 1022-1032.	2.7	106
13	Histone deacetylases: salesmen and customers in the postâ€translational modification market. Biology of the Cell, 2009, 101, 193-205.	0.7	97
14	Survivin and YM155: How faithful is the liaison?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 202-220.	3.3	90
15	Phosphorylationâ€“acetylation switch in the regulation of STAT1 signaling. Molecular and Cellular Endocrinology, 2010, 315, 40-48.	1.6	87
16	Acetylation modulates the STAT signaling code. Cytokine and Growth Factor Reviews, 2012, 23, 293-305.	3.2	79
17	Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research, 2016, 76, 3067-3077.	0.4	75
18	Mechanism for ubiquitylation of the leukemia fusion proteins AML1â€ETO and PMLâ€RARÎ±. FASEB Journal, 2008, 22, 1369-1379.	0.2	74

#	Article	IF	Citations
19	Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. Journal of Molecular Cell Biology, 2012, 4, 284-293.	1.5	70
20	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. Journal of Proteomics, 2013, 85, 109-128.	1.2	64
21	Concepts to Target MYC in Pancreatic Cancer. Molecular Cancer Therapeutics, 2016, 15, 1792-1798.	1.9	64
22	NFÎºB/p53 crosstalkâ€"a promising new therapeutic target. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 90-103.	3.3	61
23	A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget, 2012, 3, 31-43.	0.8	60
24	MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Research, 2014, 42, 10433-10447.	6.5	58
25	HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. Nature Communications, 2018, 9, 764.	5.8	58
26	Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 524-538.	3.3	57
27	The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Archives of Toxicology, 2018, 92, 2227-2243.	1.9	57
28	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 3454-3477.	2.9	56
29	PML promotes MHC class II gene expression by stabilizing the class II transactivator. Journal of Cell Biology, 2012, 199, 49-63.	2.3	54
30	MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle, 2012, 11, 1593-1602.	1.3	48
31	Histone deacetylase inhibitors block IFNÎ³-induced STAT1 phosphorylation. Cellular Signalling, 2012, 24, 1453-1460.	1.7	47
32	Interstrand Crosslink Repair as a Target for HDAC Inhibition. Trends in Pharmacological Sciences, 2017, 38, 822-836.	4.0	47
33	Cell-based Analysis of Structure-Function Activity of Threonine Aspartase 1. Journal of Biological Chemistry, 2011, 286, 3007-3017.	1.6	45
34	A p300 and SIRT1 Regulated Acetylation Switch of C/EBPÎ± Controls Mitochondrial Function. Cell Reports, 2018, 22, 497-511.	2.9	45
35	Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 29-39.	3.3	43
36	Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget, 2015, 6, 33755-33768.	0.8	42

#	Article	IF	Citations
37	Class I histone deacetylases regulate p53/NF-Î°B crosstalk in cancer cells. Cellular Signalling, 2017, 29, 218-225.	1.7	41
38	Sumoylation of HDAC2 promotes NF-Î°B-dependent gene expression. Oncotarget, 2015, 6, 7123-7135.	0.8	40
39	Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells. Clinical Cancer Research, 2012, 18, 417-431.	3.2	38
40	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915.	1.1	38
41	Acetylation as a Transcriptional Control Mechanismâ€"HDACs and HATs in Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Cancer, 2011, 42, 85-92.	0.6	37
42	Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 343-356.	1.2	37
43	Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors. Molecular Cancer Therapeutics, 2012, 11, 2373-2383.	1.9	35
44	MTOR inhibitor-based combination therapies for pancreatic cancer. British Journal of Cancer, 2018, 118, 366-377.	2.9	35
45	Design and biological evaluation of tetrahydro-Î²-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 329-357.	2.6	34
46	The Importinâ€Alpha/Nucleophosmin Switch Controls Taspase1 Protease Function. Traffic, 2011, 12, 703-714.	1.3	32
47	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. Cellular Signalling, 2017, 39, 9-17.	1.7	32
48	SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget, 2014, 5, 3184-3196.	0.8	31
49	Caspase-8-mediated PAR-4 cleavage is required for TNFÎ±-induced apoptosis. Oncotarget, 2014, 5, 2988-2998.	0.8	30
50	Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. Cellular Oncology (Dordrecht), 2017, 40, 549-561.	2.1	28
51	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	2.9	28
52	Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. International Journal of Molecular Sciences, 2022, 23, 369.	1.8	28
53	Targeting histone deacetylases in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2010, 14, 1255-1263.	1.6	27
54	HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of Î²-catenin, MYC, and WT1. Cancers, 2019, 11, 1436.	1.7	27

#	Article	IF	Citations
55	Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53â€independent pancreatic cancer cell death. International Journal of Cancer, 2013, 132, 2248-2257.	2.3	26
56	Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. Archives of Toxicology, 2017, 91, 2191-2208.	1.9	26
57	STAT1â€HDAC4 signaling induces epithelialâ€mesenchymal transition and sphere formation of cancer cells overexpressing the oncogene, CUG2. Oncology Reports, 2018, 40, 2619-2627.	1.2	26
58	Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle, 2012, 11, 3219-3226.	1.3	25
59	Differential regulation of PMLâ€“RARÎ± stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. International Journal of Biochemistry and Cell Biology, 2012, 44, 132-138.	1.2	23
60	The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers. Cytokine and Growth Factor Reviews, 2015, 26, 405-413.	3.2	23
61	Allosteric inhibition of Taspase1â€²s pathobiological activity by enforced dimerization<i>in vivo</i>. FASEB Journal, 2012, 26, 3421-3429.	0.2	22
62	How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot. Methods in Molecular Biology, 2017, 1510, 355-364.	0.4	21
63	Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2263-2273.	1.2	19
64	Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewingâ€™s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity. Journal of Cancer Research and Clinical Oncology, 2016, 142, 17-26.	1.2	19
65	The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188453.	3.3	19
66	Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. Oncotarget, 2018, 9, 27835-27850.	0.8	19
67	HDAC2 Facilitates Pancreatic Cancer Metastasis. Cancer Research, 2022, 82, 695-707.	0.4	19
68	STAT5 acetylation. Jak-stat, 2013, 2, e26102.	2.2	18
69	JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter. Biochemical Pharmacology, 2015, 96, 52-64.	2.0	18
70	SUMOylation regulates the intracellular fate of ZO-2. Cellular and Molecular Life Sciences, 2017, 74, 373-392.	2.4	18
71	PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. Scientific Reports, 2019, 9, 8755.	1.6	16
72	A ZEB1-HDAC pathway enters the epithelial to mesenchymal transition world in pancreatic cancer: Figure 1. Gut, 2012, 61, 329-330.	6.1	15

#	Article	IF	Citations
73	RETRA exerts anticancer activity in Ewingâ€™s sarcoma cells independent of their TP53 status. European Journal of Cancer, 2015, 51, 841-851.	1.3	15
74	Mechanistic insights into p53â€regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Molecular Oncology, 2021, 15, 3404-3429.	2.1	15
75	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry, 2022, 234, 114272.	2.6	15
76	Targeting the ubiquitinâ€proteasome system in a pancreatic cancer subtype with hyperactive MYC. Molecular Oncology, 2020, 14, 3048-3064.	2.1	13
77	TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases. Oncotarget, 2015, 6, 28833-28850.	0.8	13
78	Acetylation and sumoylation control STAT5 activation antagonistically. Jak-stat, 2012, 1, 203-207.	2.2	12
79	Establishment and characterization of HROC69â€‰â€“â€‰a CrohnÂ´s related colonic carcinoma cell line and its matched patient-derived xenograft. Scientific Reports, 2016, 6, 24671.	1.6	12
80	Human platelet lysate as validated replacement for animal serum to assess chemosensitivity. ALTEX: Alternatives To Animal Experimentation, 2019, 36, 277-288.	0.9	12
81	Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells. Oncotarget, 2015, 6, 5354-5368.	0.8	12
82	Caspase-3 and Caspase-6 cleave STAT1 in leukemic cells. Oncotarget, 2014, 5, 2305-2317.	0.8	11
83	Pasteurella multocida toxin- induced osteoclastogenesis requires mTOR activation. Cell Communication and Signaling, 2015, 13, 40.	2.7	11
84	Overexpression of the Catalytically Impaired Taspase1T234V or Taspase1D233A Variants Does Not Have a Dominant Negative Effect in T(4;11) Leukemia Cells. PLoS ONE, 2012, 7, e34142.	1.1	11
85	Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World Journal of Gastroenterology, 2018, 24, 3749-3759.	1.4	11
86	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Archives of Toxicology, 2022, 96, 177-193.	1.9	10
87	Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discovery Today Disease Mechanisms, 2007, 4, 277-283.	0.8	9
88	Acetylation of Endogenous STAT Proteins. Methods in Molecular Biology, 2013, 967, 167-178.	0.4	9
89	Fly versus man: evolutionary impairment of nucleolar targeting affects the degradome of Drosophila's Taspase1. FASEB Journal, 2015, 29, 1973-1985.	0.2	9
90	Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. Archives of Toxicology, 2018, 92, 2119-2135.	1.9	9

#	Article	IF	Citations
91	Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell Chemical Biology, 2022, 29, 398-411.e4.	2.5	9
92	Arginine residues within the DNA binding domain of STAT3 promote intracellular shuttling and phosphorylation of STAT3. Cellular Signalling, 2014, 26, 1698-1706.	1.7	8
93	A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. European Journal of Medicinal Chemistry, 2020, 193, 112232.	2.6	8
94	Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer & Metabolism, 2022, 10, .	2.4	8
95	STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling. Cytokine, 2021, 144, 155552.	1.4	7
96	Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines. World Journal of Gastroenterology, 2018, 24, 4880-4892.	1.4	7
97	The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration. Cytokine and Growth Factor Reviews, 2017, 37, 29-45.	3.2	6
98	Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Cells, 2021, 10, 2520.	1.8	6
99	The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. Cell Biology and Toxicology, 2023, 39, 2401-2419.	2.4	6
100	Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses. Cellular Signalling, 2013, 25, 989-998.	1.7	5
101	PNUTS at the crossroads of tumorigenesis and metastasis formation. Journal of Thoracic Disease, 2018, 10, 560-563.	0.6	5
102	DNA replication dynamics of vole genome and its epigenetic regulation. Epigenetics and Chromatin, 2019, 12, 18.	1.8	5
103	Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2**. ChemBioChem, 2021, 22, 861-864.	1.3	5
104	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
105	Microsatellite Status and IÎºBÎ± Expression Levels Predict Sensitivity to Pharmaceutical Curcumin in Colorectal Cancer Cells. Cancers, 2022, 14, 1032.	1.7	4
106	Detection of Autophagy Induction After HDAC Inhibitor Treatment in Leukemic Cells. Methods in Molecular Biology, 2017, 1510, 3-10.	0.4	3
107	Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology, 2021, 21, 912-919.	0.5	3
108	Singleâ€cell profiling guided combination therapy of câ€Fos and histone deacetylase inhibitors in diffuse large Bâ€cell lymphoma. Clinical and Translational Medicine, 2022, 12, .	1.7	3

#	Article	IF	Citations
109	Analyzing the Impact of Pan- and Class-Specific HDACi on Differentiation-Associated Factors. Methods in Molecular Biology, 2017, 1510, 375-385.	0.4	2
110	RNA interference protocol to silence oncogenic drivers in leukemia cell lines. STAR Protocols, 2022, 3, 101512.	0.5	2
111	Impact of the STAT1 N-terminal domain for fibrosarcoma cell responses to É£-irradiation. Experimental Results, 2020, 1, .	0.2	1
112	News and views. Archives of Toxicology, 2022, 96, 2143-2144.	1.9	1
113	Novel insight into mechanisms for ATR activation by chromatin structures. Archives of Toxicology, 2021, 95, 3433-3434.	1.9	0
114	WT1 Protects Leukemic Cells from Cytotoxic Replicative Stress. Blood, 2014, 124, 880-880.	0.6	0